Dietrich Wilhelm Beelen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Dietrich Wilhelm Beelen has a total of 517 co-authors. Here are the top co-authors by number of shared publications:
- Nicolaus Kröger
University Hospital Eppendorf, Hamburg, Germany
32 shared publications - Peter Dreger
Department Medicine V, University of Heidelberg, Heidelberg, Germany
27 shared publications - Didier Blaise
Departement D’Hematologie, Programme de Transplantation et de Therapie Cellulaire, Centre de Recherche en Cancerologie de Marseille, Institut Paoli Calmettes, Marseille, France
26 shared publications - Guido Kobbe
Department of Hematology, Oncology and Clinical Immunology, University Hospital Düsseldorf, Heinrich Heine University, Medical Faculty, Düsseldorf, Germany
25 shared publications - Maija Itälä-Remes
Department of Clinical Hematology and Stem Cell Transplantations, Turku University Hospital, Turku, Finland
25 shared publications - Carlos Solano
Hospital Clínico Universitario-INCLIVA, University of Valencia, Valencia, Spain
24 shared publications
Latest Publications
- 25 June 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (23) , 2221-2232
Donor Selection and Human Leukocyte Antigen Loss Leukemia Relapse After Hematopoietic Cell Transplantation
PURPOSE: For patients with hematologic malignancies, relapse is the leading cause of death after allogeneic hematopoietic cell transplantation (allo-HCT). Frequently, relapses are explained by immune evasion through alterations of human leukocyte antigens (HLAs), but determinants and clinical consequences remain poorly defined. METHODS: We analyzed 533 relapses of hematologic cancers after allo-HCT from different donor types, conducted at 27 centers worldwide. Genomic loss of mismatched HLA (HLA loss) was assessed using a newly developed next-generation sequencing pipeline. Clinical and immunogenetic factors associated with HLA loss were evaluated. Using HLA data from approximately 5 million individuals, a web-based tool to infer HLA incompatibility phasing was developed. RESULTS: HLA loss occurred in 15.6% of relapses, with significant variation according to donor type (28.7% haploidentical family, 7.2% unrelated adult, 2.7% cord blood, P < .0001). The distribution of HLA mismatches across the patient's haplotypes, predicted through the phasing tool, was strongly associated with HLA loss, with an incidence of 27.6% when HLA mismatches were in the same haplotype, compared with 5.4% if present on different haplotypes ( P < .0001). HLA loss affected postrelapse outcomes, abrogating the efficacy of original donor lymphocyte infusions, with significant survival advantage by second allo-HCT from a different donor. CONCLUSION: The likelihood of HLA loss varies significantly according to the number and positioning of HLA mismatches between patient and donor. A newly developed phasing tool enables reliable prediction of its risk, supporting informed donor selection. Routine assessment of HLA loss at relapse is warranted, as it critically affects the success of immunologic salvage therapies.
- 25 June 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (23) , 2221-2232
Donor Selection and Human Leukocyte Antigen Loss Leukemia Relapse After Hematopoietic Cell Transplantation
PURPOSE: For patients with hematologic malignancies, relapse is the leading cause of death after allogeneic hematopoietic cell transplantation (allo-HCT). Frequently, relapses are explained by immune evasion through alterations of human leukocyte antigens (HLAs), but determinants and clinical consequences remain poorly defined. METHODS: We analyzed 533 relapses of hematologic cancers after allo-HCT from different donor types, conducted at 27 centers worldwide. Genomic loss of mismatched HLA (HLA loss) was assessed using a newly developed next-generation sequencing pipeline. Clinical and immunogenetic factors associated with HLA loss were evaluated. Using HLA data from approximately 5 million individuals, a web-based tool to infer HLA incompatibility phasing was developed. RESULTS: HLA loss occurred in 15.6% of relapses, with significant variation according to donor type (28.7% haploidentical family, 7.2% unrelated adult, 2.7% cord blood, P < .0001). The distribution of HLA mismatches across the patient's haplotypes, predicted through the phasing tool, was strongly associated with HLA loss, with an incidence of 27.6% when HLA mismatches were in the same haplotype, compared with 5.4% if present on different haplotypes ( P < .0001). HLA loss affected postrelapse outcomes, abrogating the efficacy of original donor lymphocyte infusions, with significant survival advantage by second allo-HCT from a different donor. CONCLUSION: The likelihood of HLA loss varies significantly according to the number and positioning of HLA mismatches between patient and donor. A newly developed phasing tool enables reliable prediction of its risk, supporting informed donor selection. Routine assessment of HLA loss at relapse is warranted, as it critically affects the success of immunologic salvage therapies.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma
Multivariate cox regression analysis of different treatments for PFS adjusting for baseline characteristics (full case analysis, ZUMA-2: n = 64, alloHCT: n = 250).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma
Multivariate cox regression analysis of different treatments for PFS adjusting for baseline characteristics (full case analysis, ZUMA-2: n = 64, alloHCT: n = 250).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma
Overall survival (OS) and progression-free survival (PFS) in the unmatched alloHCT cohort based on response status before alloHCT.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma
Overall survival (OS) and progression-free survival (PFS) in the unmatched alloHCT cohort based on response status before alloHCT.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma
Multivariate cox regression analysis of different treatments for OS adjusting for baseline characteristics (ZUMA-2: n = 64, alloHCT: n = 272)
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma
Multivariate cox regression analysis of different treatments for OS adjusting for baseline characteristics (ZUMA-2: n = 64, alloHCT: n = 272)
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma
Comparison of ZUMA-2 and alloHCT population for Overall survival (OS), Progression-free survival (PFS), Non-relapse mortality (NRM) and incidence of relapse (IR) in unmatched cohorts.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma
Comparison of ZUMA-2 and alloHCT population for Overall survival (OS), Progression-free survival (PFS), Non-relapse mortality (NRM) and incidence of relapse (IR) in unmatched cohorts.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma
Flow chart presenting inclusion and exclusion of patients used for final propensity score-matched analysis.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma
Flow chart presenting inclusion and exclusion of patients used for final propensity score-matched analysis.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma
Density plots for each covariate used for propensity score matching before and after matching.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma
Density plots for each covariate used for propensity score matching before and after matching.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S6 from Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma
Acute and chronic Graft-versus-host-disease in the total alloHCT cohort based on full case analysis.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S6 from Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma
Acute and chronic Graft-versus-host-disease in the total alloHCT cohort based on full case analysis.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma
Characteristics of transplant procedure in alloHCT cohort before and after matching.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma
Characteristics of transplant procedure in alloHCT cohort before and after matching.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S5 from Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma
Multivariate cause-specific hazard regression analysis of different treatments for IR in a competing risk setting adjusting for baseline characteristics (full case analysis, ZUMA-2: n = 64, alloHCT: n = 250).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma
Multivariate cause-specific hazard regression analysis of different treatments for IR in a competing risk setting adjusting for baseline characteristics (full case analysis, ZUMA-2: n = 64, alloHCT: n = 250).